Year |
Citation |
Score |
2020 |
Lin KH, Rutter JC, Xie A, Pardieu B, Winn ET, Bello RD, Forget A, Itzykson R, Ahn YR, Dai Z, Sobhan RT, Anderson GR, Singleton KR, Decker AE, Winter PS, et al. Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer. Nature Genetics. PMID 32203462 DOI: 10.1038/S41588-020-0590-9 |
0.302 |
|
2019 |
Hinz TK, Kleczko EK, Singleton KR, Calhoun J, Marek LA, Kim J, Tan AC, Heasley LE. Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines. Molecular Pharmacology. PMID 31554698 DOI: 10.1124/Mol.119.117804 |
0.786 |
|
2018 |
Pilling AB, Kim J, Estrada-Bernal A, Zhou Q, Le AT, Singleton KR, Heasley LE, Tan AC, DeGregori J, Doebele RC. ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget. 9: 8823-8835. PMID 29507657 DOI: 10.18632/Oncotarget.24260 |
0.679 |
|
2017 |
Singleton KR, Crawford L, Tsui E, Manchester HE, Maertens O, Liu X, Liberti MV, Magpusao AN, Stein EM, Tingley JP, Frederick DT, Boland GM, Flaherty KT, McCall SJ, Krepler C, et al. Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. Cell Reports. 21: 2796-2812. PMID 29212027 DOI: 10.1016/J.Celrep.2017.11.022 |
0.377 |
|
2017 |
Singleton KR, Earley KT, Heasley LE. Analysis of Drug Resistance Using Kinome-Wide Functional Screens. Methods in Molecular Biology (Clifton, N.J.). 1636: 163-177. PMID 28730479 DOI: 10.1007/978-1-4939-7154-1_11 |
0.619 |
|
2016 |
Singleton KR, Wood KC. Narrowing the focus: a toolkit to systematically connect oncogenic signaling pathways with cancer phenotypes. Genes & Cancer. 7: 218-228. PMID 27738492 DOI: 10.18632/genesandcancer.112 |
0.327 |
|
2015 |
Singleton KR, Hinz TK, Kleczko EK, Marek LA, Kwak J, Harp T, Kim J, Tan AC, Heasley LE. Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC. Cancer Research. 75: 4398-406. PMID 26359452 DOI: 10.1158/0008-5472.Can-15-0509 |
0.771 |
|
2015 |
Kleczko EK, Kim J, Keysar SB, Heasley LR, Eagles JR, Simon M, Marshall ME, Singleton KR, Jimeno A, Tan AC, Heasley LE. An Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases. Plos One. 10: e0123600. PMID 25946135 DOI: 10.1371/Journal.Pone.0123600 |
0.778 |
|
2014 |
Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff M, Chen PL, Rathmell JC, et al. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Science Signaling. 7: ra121. PMID 25538079 DOI: 10.1126/Scisignal.Aaa1877 |
0.419 |
|
2014 |
Kim J, Vasu VT, Mishra R, Singleton KR, Yoo M, Leach SM, Farias-Hesson E, Mason RJ, Kang J, Ramamoorthy P, Kern JA, Heasley LE, Finigan JH, Tan AC. Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy. Bioinformatics (Oxford, England). 30: 2393-8. PMID 24812339 DOI: 10.1093/Bioinformatics/Btu323 |
0.751 |
|
2013 |
Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, Cummings CT, Graham DK, Astling D, Tan AC, Heasley LE. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis. 2: e39. PMID 23552882 DOI: 10.1038/oncsis.2013.4 |
0.689 |
|
2013 |
Singleton KR, Kim J, Hinz TK, Marek LA, Casás-Selves M, Hatheway C, Tan AC, DeGregori J, Heasley LE. A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines. Molecular Pharmacology. 83: 882-93. PMID 23371912 DOI: 10.1124/Mol.112.084111 |
0.774 |
|
2012 |
Singleton KR, Tan A, Kim J, Heasley L. Abstract B35: Alternate receptor tyrosine kinases provide protection from FGFR inhibition in HNSCC cells as identified by genome-wide shRNA screening Clinical Cancer Research. 18: B35-B35. DOI: 10.1158/1078-0432.Mechres-B35 |
0.806 |
|
2011 |
Marshall ME, Hinz TK, Kono SA, Singleton KR, Bichon B, Ware KE, Marek L, Frederick BA, Raben D, Heasley LE. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5016-25. PMID 21673064 DOI: 10.1158/1078-0432.Ccr-11-0050 |
0.745 |
|
Show low-probability matches. |